109 related articles for article (PubMed ID: 19951065)
1. Anti-NuMA antibodies in a psoriatic patient: considerations about clinical relevance and effect of infliximab treatment.
Tampoia M; Mastrandrea V; Cassano N; Vena GA
Immunopharmacol Immunotoxicol; 2009; 31(1):127-9. PubMed ID: 19951065
[TBL] [Abstract][Full Text] [Related]
2. Two major autoantigen-antibody systems of the mitotic spindle apparatus.
Andrade LE; Chan EK; Peebles CL; Tan EM
Arthritis Rheum; 1996 Oct; 39(10):1643-53. PubMed ID: 8843854
[TBL] [Abstract][Full Text] [Related]
3. The spindle kinesin-like protein HsEg5 is an autoantigen in systemic lupus erythematosus.
Whitehead CM; Winkfein RJ; Fritzler MJ; Rattner JB
Arthritis Rheum; 1996 Oct; 39(10):1635-42. PubMed ID: 8843853
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to mitotic apparatus: association with other autoantibodies and their clinical significance.
Bonaci-Nikolic B; Andrejevic S; Bukilica M; Urosevic I; Nikolic M
J Clin Immunol; 2006 Sep; 26(5):438-46. PubMed ID: 16941236
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to mitotic spindle apparatus: clinical significance of NuMA and HsEg5 autoantibodies.
Mozo L; Gutiérrez C; Gómez J
J Clin Immunol; 2008 Jul; 28(4):285-90. PubMed ID: 18240009
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies in psoriatic patients treated with anti-TNF-α therapy.
Bardazzi F; Odorici G; Virdi A; Antonucci VA; Tengattini V; Patrizi A; Balestri R
J Dtsch Dermatol Ges; 2014 May; 12(5):401-6. PubMed ID: 24797746
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies to nuclear mitotic apparatus in a patient with vitiligo and autoimmune thyroiditis.
Auer-Grumbach P; Stangl M
Dermatology; 1993; 186(3):229-31. PubMed ID: 8453154
[TBL] [Abstract][Full Text] [Related]
8. NuMA protein is a human autoantigen.
Price CM; McCarty GA; Pettijohn DE
Arthritis Rheum; 1984 Jul; 27(7):774-9. PubMed ID: 6378210
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.
Hoffmann JH; Hartmann M; Enk AH; Hadaschik EN
Br J Dermatol; 2011 Dec; 165(6):1355-8. PubMed ID: 21801160
[TBL] [Abstract][Full Text] [Related]
10. Uncommon patterns of antinuclear antibodies recognizing mitotic spindle apparatus antigens and clinical associations.
Betancur JF; Londoño A; Estrada VE; Puerta SL; Osorno SM; Loaiza A; Carmona JA; Gómez-Puerta JA
Medicine (Baltimore); 2018 Aug; 97(34):e11727. PubMed ID: 30142759
[TBL] [Abstract][Full Text] [Related]
11. Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review.
Chimenti MS; Spinelli FR; Giunta A; Martinelli F; Saraceno R; Conti F; Perricone R; Valesini G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S61-3. PubMed ID: 25381980
[TBL] [Abstract][Full Text] [Related]
12. Infliximab in psoriasis and psoriatic arthritis.
Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
[TBL] [Abstract][Full Text] [Related]
13. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
[TBL] [Abstract][Full Text] [Related]
14. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
15. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study.
Pink AE; Fonia A; Allen MH; Smith CH; Barker JN
Br J Dermatol; 2010 Apr; 162(4):780-5. PubMed ID: 19863499
[TBL] [Abstract][Full Text] [Related]
16. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
[TBL] [Abstract][Full Text] [Related]
17. Biologic therapies in psoriasis: a new therapeutic approach.
Gisondi P; Girolomoni G
Autoimmun Rev; 2007 Sep; 6(8):515-9. PubMed ID: 17854741
[TBL] [Abstract][Full Text] [Related]
18. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
19. Influence of infliximab on keratinocyte apoptosis in psoriasis patients.
Raho G; Vena GA; Bizzoca A; Cassano N; Garofalo E; Congedo M; Gennarini G
Immunopharmacol Immunotoxicol; 2011 Mar; 33(1):227-31. PubMed ID: 20507213
[TBL] [Abstract][Full Text] [Related]
20. Osteomyelitis occurring during infliximab treatment of severe psoriasis.
Sri JC; Tsai CL; Deng A; Gaspari AA
J Drugs Dermatol; 2007 Feb; 6(2):207-10. PubMed ID: 17373180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
